Selecting a Preclinical CRO: Evaluation Criteria, Key Questions, and Common Pitfallsㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤㅤ

You have completed bench testing for your medical device, your in vitro data look promising, and the next critical decision is approaching: which preclinical contract research organization (CRO) is the right fit for your project?

Choosing the right CRO affects more than timeline and budget. It can have a meaningful impact on how well your data support regulatory review or whether additional questions or repeat studies become necessary. Repeating a GLP study is one of the most costly setbacks a MedTech startup can face. Even so, CRO selection for medical devices is surprisingly often based on a single proposal, a recommendation from someone in the network, and a good gut feeling. This article provides a structured approach: when a preclinical CRO is actually useful, how to clearly separate responsibilities, and which eight questions you should ask every potential partner.

Series note: This article addresses the operational question of how to systematically select a preclinical CRO and structure the collaboration. The upstream questions of regulatory evidence strategy — which studies are needed, when, and in which sequence — are covered in the article on preclinical development. The two articles complement each other: strategy there, operational partner selection here.

When a Preclinical CRO Makes Sense — and When It May Not

Not every preclinical project requires an external CRO. The following scenarios provide practical orientation.

Four Trigger Scenarios in Which a Preclinical CRO Is Often the Right Choice

01	GLP requirements for safety and toxicology studies Good Laboratory Practice (GLP) according to 21 CFR Part 58 and the OECD principles may be required or expected for certain safety-relevant nonclinical studies. This applies particularly where the study is intended to support an FDA submission, such as an Investigational Device Exemption (IDE), or to contribute toxicological or biological evaluation data to an ISO 10993-based evidence strategy under the EU MDR (Medical Device Regulation). GLP requires an independent quality assurance team, validated processes, ALCOA+ compliant documentation (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available), and comprehensive raw data archiving. Importantly, GLP does not apply to all regulatorily relevant studies. Purely mechanical performance tests and bench tests are often not subject to GLP requirements but require a robust quality management system, typically laboratory accreditation according to ISO/IEC 17025. An experienced preclinical CRO should be able to assess early which tests need to be conducted in compliance with GLP and which non-GLP tests can be covered in a robust manner through suitable laboratories, for example laboratories accredited according to ISO/IEC 17025.
02	Large animal models with surgical complexity An implant study in a porcine model with a catheterization laboratory, fluoroscopy, and a 30-day survival phase requires surgeons with preclinical experience as well as operating room infrastructure comparable to human medical standards. Depending on the research question, small animal models such as rat or rabbit models may also be used. The decisive factor is the combination of clinically oriented surgical expertise and sound laboratory animal expertise, supported by veterinarians. In practice, surgical experience in complex large animal models in particular is often the limiting factor. Building this type of setup internally involves substantial investment and can quickly cost several million euros per year. The following principle applies: According to ISO 10993-1:2025, biological evaluation of a medical device should generally begin with chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17), provided this is appropriate within the risk-based approach. Only when these analyses indicate potential risks or do not adequately address the question may in vivo studies become necessary. A modern preclinical CRO should therefore not only bring operational expertise, but also ensure that analytics and toxicological assessment are incorporated into study planning early, either internally or through qualified partners.
03	Time pressure caused by regulatory deadlines If the regulatory IDE submission is scheduled for six months from now, a specialized CRO has a meaningful advantage: established workflows, available animal models, and a team that can start quickly. Experienced CROs typically require a start-up period of several weeks, whereas internal setup often takes several months.
04	Missing histopathology expertise Histopathological evaluation is the most frequently underestimated bottleneck in preclinical MedTech studies. Toxicologic pathologists with MedTech specialization are among the scarcest resources worldwide in preclinical research, a structural bottleneck that is reflected in long waiting times at external laboratories. The decisive factor is not only whether histopathology is performed internally or externally, but how early pathology experts are involved in study design, sample processing, evaluation, and report preparation. A CRO with established partner laboratories and clear review processes can support equally robust and well-coordinated outcomes.

When Internal Resources May Be Sufficient and What This Requires

Non-GLP feasibility studies with a purely exploratory objective may be suitable for internal execution, provided the required laboratory animal expertise, regulatory approvals, veterinary care, suitable infrastructure, and sufficient capacity are available. As a rule of thumb: as soon as your study is regulatorily relevant, involves large animals, or requires GLP-relevant safety endpoints, collaboration with a preclinical CRO is recommended.

Defining Responsibilities Between Sponsor and CRO

One of the most common sources of conflict between sponsors and preclinical CROs is unclear responsibility allocation. Two levels must be distinguished:

Overall strategic responsibility for the medical device and its regulatory pathway always remains with the sponsor. Scientific responsibility for the study plan, conduct, and report, on the other hand, lies with the CRO study director in the GLP context. The study director carries primary responsibility for GLP-compliant study conduct and reporting, including animal model selection. The required inputs, however, must be provided by the sponsor.

Principle: The boundary is reached where influence could compromise the independence of scientific findings, for example through pressure on interpretation or selective reporting of results. This boundary is not a bureaucratic detail, but a regulatory safeguard for both sides: it helps protect the regulatory usability of the study.

What the Sponsor Must Provide Before Study Start

Five inputs are essential:

• Product description (mode of action, materials, sterilization method)
• Intended purpose
• Regulatory objective (510(k), IDE, PMA, or CE marking)
• Budget framework
• Timeline

The status of the design freeze is decisive. For pivotal GLP studies, the device should typically be sufficiently design-stable and production-equivalent. Changes to the product design after study initiation may compromise the validity of the study.

What the CRO Typically Covers — and Where the Boundary Lies

A preclinical CRO typically takes on:

• study planning and protocol development,
• operational execution,
• animal monitoring,
• coordination of the relevant evaluations, including histopathology, and
• preparation of the final report.

Individual specialized services may be integrated through qualified partner laboratories, depending on the setup. The study director holds overall scientific responsibility. In GLP studies, the CRO is additionally responsible for QA audits (quality assurance) and ALCOA+ compliant documentation.

The following scope of work is typically not assumed by the preclinical CRO:

• overall regulatory strategy,
• implementation of an ISO 13485 quality management system, and
• regulatory submission.

Simplified RACI (Responsible, Accountable, Consulted, Informed)

Activity	Planning	Execution	Reporting
Regulatory strategy	Sponsor (R/A)	Sponsor (A)	Sponsor (R/A)
Study design & protocol	CRO (R/A) · Sponsor (C)	—	—
Product provision	Sponsor (R/A)	Sponsor (R/A)	—
Animal model selection	CRO (R/A) · Sponsor (C)	—	—
Surgery & animal monitoring	—	CRO (R/A)	—
Histopathology	—	CRO (R/A)	CRO (R/A) · Sponsor (C)
Quality assurance (GLP)	CRO (R/A)	CRO (R/A)	CRO (R/A)
Final report	—	—	CRO (R/A)
Regulatory submission	—	—	Sponsor (R/A)

R = Responsible · A = Accountable · C = Consulted · I = Informed
According to OECD GLP principles and 21 CFR Part 58, the study director has overall responsibility for the scientific and technical conduct of the study and the final report. This includes responsibility for the study plan, protocol amendments, interpretation of results, and reporting. The sponsor remains responsible for providing the regulatory objective, device information, intended use, and submission context.

Eight Core Questions for CRO Selection

Finding the right preclinical CRO requires more than a price comparison. The following eight questions cover the three decisive areas of competence and can be used as systematic CRO selection criteria.

A: Expertise and Animal Models

Question 1: What experience does the CRO have with my product type and indication?
Ask to see reference studies with comparable products, not merely a list of capabilities.

Question 2: Which animal models are available, and what scientific rationale does the CRO provide for recommending a specific model for your project?
Also ask how existing or planned data from chemical characterization according to ISO 10993-18 and toxicological risk assessment are incorporated into the planning of potential in vivo studies, regardless of whether these services are provided internally or through qualified partners. This shows whether the CRO understands the current state of regulatory science.

Question 3: Does the CRO have the appropriate GLP compliance status, and for which study types?
GLP compliance should not be assessed generically: clarify whether the test facility has appropriate GLP compliance status or a corresponding GLP certificate for the relevant study type, model, and planned endpoints. A preclinical CRO may be certified for biocompatibility testing but not for large animal implantation studies.

B: Quality and Documentation

Question 4: Is the laboratory accredited according to ISO/IEC 17025, and for which test methods?
Clarify whether relevant accredited methods are available for the specific tests required, for example in standardized biocompatibility testing. ISO/IEC 17025 accreditation is an important quality indicator where it applies to the specific test method needed. For preclinical surgical or animal experimental evaluation studies, however, project-specific study designs, GLP compliance, study director responsibility, SOPs, raw data documentation, and auditable processes are often more central. CRO knowledge of ISO 13485 is additionally useful. As a manufacturer standard, however, ISO 13485 describes the quality management system (QMS), not laboratory testing competence.

Question 5: How are raw data archived, and does the concept cover both FDA and EU MDR timelines?
FDA 21 CFR 58.195 defines minimum retention periods. In practice, it must be clarified how these align with longer requirements, for example under the EU MDR on the manufacturer side. These must be distinguished from the manufacturer’s retention obligations under the EU MDR, particularly for technical documentation. Therefore, before study start, clarify which raw data, reports, and archive information the CRO will retain long term and which documents the sponsor must transfer into the technical documentation in a timely manner. Clarify whether the CRO offers a long-term archiving concept or whether you as the sponsor must take over the raw data in due time.

Question 6: How does the CRO handle protocol deviations?
Every deviation must be authorized and documented by the study director. More important than a generic statement that no deviations occur is a clearly documented, audit-ready process for handling protocol deviations.

C: Communication and Timeline

Question 7: Who is my dedicated point of contact, and will this person remain involved throughout the entire project?
Personnel continuity is one of the most important but least frequently asked factors in CRO selection for medical devices.

Question 8: Which review points are planned, and how are unexpected findings escalated?
Final scientific decision-making authority lies with the CRO study director. A strong partner escalates relevant findings proactively before they are finalized in the report.

Initial Evaluation Questionnaire

#	Core question	Category	Rating (1–5)
1	Experience with my product type and indication?	Expertise	☐ ☐ ☐ ☐ ☐
2	Which animal models are recommended — and what is the rationale?	Expertise	☐ ☐ ☐ ☐ ☐
3	GLP certification or compliance status available for the relevant study types?	Expertise	☐ ☐ ☐ ☐ ☐
4	ISO/IEC 17025 only where methodologically relevant: is the specific test method accredited, for example for biocompatibility testing?	Quality	☐ ☐ ☐ ☐ ☐
5	Archiving concept: does it address FDA shortest-period logic and EU MDR retention periods (10/15 years)?	Quality	☐ ☐ ☐ ☐ ☐
6	Process for protocol deviations documented by the study director?	Quality	☐ ☐ ☐ ☐ ☐
7	Dedicated point of contact throughout the entire project?	Communication	☐ ☐ ☐ ☐ ☐
8	Review points and escalation pathway for unexpected findings?	Communication	☐ ☐ ☐ ☐ ☐

1 — requirements are not met; 5 — requirements are fully met

Common Misunderstandings in CRO Collaboration

“The CRO plans everything” — why sponsor inputs are critical

Yes, a preclinical CRO develops the study protocol and recommends the animal model. But the quality of the output depends directly on the quality of your inputs. A typical example is an imprecise request such as: “We need a preclinical study for our implant.” If the regulatory objective, intended purpose, and product status are missing, additional alignment loops in protocol drafting and avoidable delays often result. According to GLP principles, the study director is responsible for the scientific design of the study plan. The more precisely you as the sponsor define your regulatory objective, intended purpose, and product status, the more efficiently the study director can develop a robust plan.

Quality vs. Speed: How a Structured Governance Model Can Support Both

Speed and quality are not mutually exclusive per se. But they require a deliberate governance model rather than ad hoc communication.

• Operational level: weekly status meetings between the study director and the sponsor’s project manager — brief, structured, and outcome-oriented
• Management level: monthly reviews with a KPI dashboard: animal health, protocol adherence, timeline status, open deviations
• Escalation level: a defined pathway with clear decision deadlines, while final scientific decision-making authority remains with the CRO study director

Transparency without micromanagement is the benchmark for effective collaboration. It can also accelerate the project because decisions are made faster and more sustainably.

Project Status — What You Should Clarify Before the Initial Consultation

The most productive initial consultations come from teams that have already aligned internally. Management or the CEO, R&D leadership, and regulatory affairs should speak with one voice about target markets, timelines, and study scope. A brief internal alignment before the initial consultation reduces follow-up questions and helps define study scope, target markets, and timelines more reliably and efficiently.

Checklist: 12 Inputs for a Productive Initial Discussion

Frequently Asked Questions About Selecting a Preclinical CRO

What does collaboration with a preclinical CRO cost, and what does it depend on?

Costs vary considerably depending on study type, animal model, duration, and GLP requirements. Key cost drivers include the number of animals, surgical complexity, histopathology scope, and reporting depth. Discuss your budget framework during the initial consultation. This supports a needs-based solution rather than the calculation of a maximum-scope protocol.

What is the difference between a MedTech CRO and a pharmaceutical CRO?

The difference is fundamental. Many pharma-oriented CROs are strongly focused on drug development, pharmacokinetics, ADME questions (absorption, distribution, metabolism, excretion), and toxicological programs. For medical devices, the focus is often on product-tissue interactions, surgical models, biological evaluation, risk management, and the integration of preclinical data into technical and regulatory documentation. A preclinical CRO specialized in MedTech is familiar with GLP principles, ISO 10993 (biological evaluation), ISO 14971 (risk management), and the EU MDR/IVDR (In Vitro Diagnostic Regulation). It understands product-tissue interactions, routinely works with surgical large animal models, and knows how preclinical data can contribute to a 510(k) or IDE submission.

Can I work with multiple CROs at the same time?

In principle, yes, for example if one CRO conducts chemical characterization and another performs implantation. For an integrated preclinical data package, it is not necessarily decisive that all services are provided internally by a single provider. What matters is that responsibilities, interfaces, data transfers, and quality assurance are clearly managed — either by one CRO as the coordinating lead partner or through a well-managed partner network.

How can I recognize a preclinical CRO specialized in MedTech?

Based on four indicators:

• Documented reference studies with medical devices, not only a pharma reference list.
• Demonstrable knowledge of GLP principles, ISO 10993, ISO 14971, and EU MDR/IVDR.
• Surgical and animal experimental expertise for the relevant preclinical question, as well as a robust concept for integrating histopathology, chemical characterization, and toxicological assessment — internally or through qualified partners.
• Experience with regulatory submissions to FDA and notified bodies, supported by specific case examples.

References & Further Reading

External References

• ISO 10993-1:2025 – Biological evaluation of medical devices — Part 1
• ISO 14971:2019 – Medical devices — Application of risk management to medical devices
• ISO/IEC 17025:2017 – General requirements for the competence of testing and calibration laboratories
• ISO 10993-18:2020 – Biological evaluation of medical devices — Part 18
• ISO 10993-17:2023 – Biological evaluation of medical devices — Part 17

Internal Links

• Medical Device Consulting: Consultant or CRO as the right next step?
• GLP-compliant practices: Clarifying the GLP level before the scoping call
• GLP vs. GLP-like: Defining the right study logic before the CRO discussion
• Preclinical Evidence: The evidence strategy as the basis for the scoping call
• Preclinical CRO Market Germany: Market overview for preselecting partners before the call
• MedTech Consulting: A DACH-specific alternative to the CRO approach
• Medical Device Commercialization: The CRO discussion as a first step toward market access

As of: May 2026 | Last reviewed: May 2026